Robert J. Whitbourn

TCT-39 Three-Year Outcomes with the Fully Repositionable and Retrievable Lotus™ Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients with Severe Aortic Stenosis: Results from the REPRISE II CE-Mark Study

The repositionable and fully retrievable Lotus™ Valve (Boston Scientific, Natick, MA, USA) was designed to facilitate accurate positioning and minimize paravalvular regurgitation in patients with severe aortic stenosis who are at high or extreme surgical risk. The device is CE-marked based on

TCT-693 Four-Year Clinical Outcomes Following TAVR with the Repositionable and Fully Retrievable Lotus Valve System: an Update from the REPRISE I Study

p<0.0001), diabetes (39.1% vs. 32.9%, p1⁄40.005), chronic obstructive pulmonary disease (35.0% vs. 26.1%, p<0.0001), atrial fibrillation (36.7% vs. 27.9%, p<0.0001) and creatinine 2mg/dL (6.9% vs. 3.1%, p1⁄40.0001) but lower STS score (5.6% vs. 6.0%, p<0.0001). In the TAVR cohort, females had more major vascular complications (11.0% vs. 5.6%, p1⁄40.002) and coronary obstruction (0.9% vs. 0%, p1⁄40.03) than males but showed a trend towards lower mortality than males (14.4% vs. 17.9%, p1⁄40.16). In the SAVR cohort, males had more acute kidney injury (39.8% vs. 29.1%, p1⁄40.0007) but no sex-related mortality difference was seen with SAVR (17.6% vs. 18.1%, p1⁄40.88). Among patients suitable for TF access, TAVR was associated with lower 2-year mortality than SAVR in women (10.8% vs. 16.5%, p1⁄40.03) [figure 1], but not in men (16.0% vs. 17.2%, p1⁄40.58). In patients not suitable for TF TAVR, no differences were seen comparing non-TF TAVR with SAVR in either males or females.

TCT-681 SOLACE AU Study: Interim results at one year of the Edwards SAPIEN XT TM Transcatheter Heart Valve in intermediate risk patients with severe aortic stenosis in Australia

We report the clinical outcomes of intermediate-risk patients at one year from the SOLACE AU Registry who received the Edwards SAPIEN XT TM Transcatheter Heart Valve (THV). This is a single arm multi-centre study in 11 centres throughout Australia of select symptomatic patients with severe aortic